Literature DB >> 28890876

Implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a meta-analysis of randomized controlled trials.

Ahmad Masri1, Muhammad Hammadah2, Evan Adelstein1, Sandeep Jain1, Samir Saba1.   

Abstract

BACKGROUND: Sudden cardiac death (SCD) is a significant cause of mortality in patients with non-ischemic cardiomyopathy (NICM). Implantable cardioverter defibrillators (ICDs) are currently indicated for the primary prevention of SCD in these patients. Conflicting results from published randomized controlled trials (RCTs) have recently questioned the protective role of ICD in NICM patients to perform an updated meta-analysis of the effect of ICDs on outcomes of NICM patients.
METHODS: We performed a search of PubMed, EMBASE, and Cochrane databases for RCTs comparing ICD to medical therapy in patients with NICM. Outcomes were all-cause mortality, SCD, and cardiac mortality. Mantel-Haenszel (MH) risk ratios (RR) were calculated using random-effects meta-analysis for the outcomes mentioned. Heterogeneity was assessed using I2 statistics and Q-statistic.
RESULTS: A total of five RCTs met the inclusion criteria, with a total of 1,503 patients in the ICD group and 1,364 patients in the medical therapy. Compared to medical therapy, ICD use resulted in a 24% relative risk reduction (RRR) of all-cause mortality (RR 0.76, 95% CI 0.64-0.91, P=0.002), and 60% RRR of SCD (RR 0.40, 95% CI 0.18-0.90, P=0.03), but was not associated with a statistically significant benefit in the prevention of cardiac mortality (RR 0.75, 95% CI 0.39-1.44, P=0.39). Limiting the analysis to patients who received an ICD only without cardiac resynchronization therapy (CRT) pacemakers (4 trials, 1,825 patients) showed similar all-cause mortality results with 24% RRR in ICD group (RR 0.76, 95% CI 0.61-0.94, P=0.01).
CONCLUSIONS: ICD therapy reduces all-cause mortality and SCD in patients with NICM.

Entities:  

Keywords:  Death; implantable defibrillators; meta-analysis; non-ischemic cardiomyopathy (NICM); randomized controlled trial (RCT)

Year:  2017        PMID: 28890876      PMCID: PMC5582055          DOI: 10.21037/cdt.2017.06.06

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  14 in total

1.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

2.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

3.  Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT).

Authors:  Dietmar Bänsch; Matthias Antz; Sigrid Boczor; Marius Volkmer; Jürgen Tebbenjohanns; Karlheinz Seidl; Michael Block; Frank Gietzen; Jürgen Berger; Karl Heinz Kuck
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

5.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

6.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

Review 7.  Idiopathic dilated cardiomyopathy.

Authors:  G W Dec; V Fuster
Journal:  N Engl J Med       Date:  1994-12-08       Impact factor: 91.245

8.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.

Authors:  Lars Køber; Jens J Thune; Jens C Nielsen; Jens Haarbo; Lars Videbæk; Eva Korup; Gunnar Jensen; Per Hildebrandt; Flemming H Steffensen; Niels E Bruun; Hans Eiskjær; Axel Brandes; Anna M Thøgersen; Finn Gustafsson; Kenneth Egstrup; Regitze Videbæk; Christian Hassager; Jesper H Svendsen; Dan E Høfsten; Christian Torp-Pedersen; Steen Pehrson
Journal:  N Engl J Med       Date:  2016-08-27       Impact factor: 91.245

9.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

10.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

View more
  4 in total

Review 1.  Should Primary Prevention ICDs Still Be Placed in Patients with Non-ischemic Cardiomyopathy? A Review of the Evidence.

Authors:  Harsha V Ganga; Abhishek Maan; E Kevin Heist
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

Review 2.  Implantable defibrillator therapy and mortality in patients with non-ischaemic dilated cardiomyopathy : An updated meta-analysis and effect on Dutch clinical practice by the Task Force of the Dutch Society of Cardiology.

Authors:  D A Theuns; T E Verstraelen; A C J van der Lingen; P P Delnoy; C P Allaart; L van Erven; A H Maass; K Vernooy; A A M Wilde; E Boersma; J G Meeder
Journal:  Neth Heart J       Date:  2022-09-06       Impact factor: 2.854

3.  Tongmai Yangxin Pill combined with metoprolol or metoprolol alone for the treatment of symptomatic premature ventricular complex: a multicenter, randomized, parallel-controlled clinical study.

Authors:  Li-Jun Liu; Guo-Hua Zhu; Hong-Yu Luo; Xi-Peng Sun; Jing Li; Qi Hua
Journal:  J Geriatr Cardiol       Date:  2022-04-28       Impact factor: 3.189

4.  Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.

Authors:  Mohamad El Moheb; Johny Nicolas; Assem M Khamis; Ghida Iskandarani; Elie A Akl; Marwan Refaat
Journal:  Cochrane Database Syst Rev       Date:  2018-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.